---
company: Organogenesis Holdings Inc.
ticker: ORGO
form: 8-K
filed: 2026-08-06
accession: 0001193125-26-338022
source: https://www.sec.gov/Archives/edgar/data/1661181/000119312526338022/
---

# Organogenesis Holdings (ORGO) earnings release, August 6, 2026

Organogenesis Holdings Inc. (ORGO) · Form 8-K, Item 2.02 · Filed 2026-08-06 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1661181/000119312526338022/)

Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results

CANTON, Mass.,

(August 6, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2026.

Second Quarter 2026 Financial Results Summary:

• Net revenue of $42.8 million for the second quarter of 2026, a decrease of $58.0 million compared to net revenue of $100.8 million for the second quarter of 2025. Net revenue for the second quarter of 2026 consists of: o

Net revenue from Advanced Wound Care products of $36.1 million, a decrease of 61% from the second quarter of 2025. o

Net revenue from Surgical & Sports Medicine products of $6.7 million, a decrease of 18% from the second quarter of 2025.

• Net loss of $96.3 million for the second quarter of 2026, compared to a net loss of $9.4 million for the second quarter of 2025, an increase in net loss of $86.9 million.

• Adjusted net loss of $89.0 million for the second quarter of 2026, compared to an adjusted net loss of $7.5 million for the second quarter of 2025, an increase in adjusted net loss of $81.5 million.

• Adjusted EBITDA loss of $34.4 million for the second quarter of 2026, compared to Adjusted EBITDA loss of $3.6 million for the second quarter of 2025, an increase in EBITDA loss of $30.7 million.

"We are encouraged by signs of measured improvement in business trends in the second quarter, though the pace of recovery from the significant market contraction is slower than we expected," said Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis. "Our business is built on efficacy and outcomes, and that is driving our expanding share as the market resets and customers turn to solutions they can trust. We remain convinced that we occupy the strongest long-term position and will remain the leader with the best evidence-based regenerative medicine products, while advancing the ReNu program to unlock new markets for the company."

Second Quarter 2026 Financial Results:

Net product revenue for the second quarter of 2026 was $42.8 million, compared to $100.8 million for the second quarter of 2025, a decrease of $58.0 million, or 58%. The decrease in net product revenue was driven by a decrease of $56.6 million, or 61%, in net product revenue for Advanced Wound Care products.

Gross profit for the second quarter of 2026 was $19.1 million, or 45% of net product revenue, compared to $73.1 million, or 73% of net product revenue for the second quarter of 2025, a decrease of $54.0 million, or 74%.

Operating expenses for the second quarter of 2026 were $94.7 million compared to $113.6 million for the second quarter of 2025, a decrease of $18.8 million, or 17%. Cost of goods sold was $23.7 million for the second quarter of 2026, compared to $27.6 million for the second quarter of 2025, a decrease of $4.0 million, or 14%.

Selling, general and administrative expenses were $54.0 million for the second quarter of 2026, compared to $73.8 million for the second quarter of 2025, a decrease of $19.8 million, or 27%. R&D expense was $18.3 million for the second quarter of 2026, compared to $10.4 million for the second quarter of 2025, an increase of $7.9 million, or 76%.

Operating loss for the second quarter of 2026 was $51.0 million, compared to an operating loss of $12.6 million for the second quarter of 2025, an increase in operating loss of $38.4 million.

Total other income, net, for the second quarter of 2026 was $0.1 million, compared to $0.7 million for the second quarter of 2025, a decrease of $0.6 million.

Net loss for the second quarter of 2026 was $96.3 million, or $(0.77) per share, compared to net loss of $9.4 million, or $(0.10) per share, for the second quarter of 2025, an increase in net loss of $86.9 million, or $(0.67) per share.

Adjusted net loss was $89.0 million for the second quarter of 2026, compared to adjusted net loss of $7.5 million for the second quarter of 2025, an increase in adjusted net loss of $81.5 million.

Adjusted EBITDA loss was $34.4 million for the second quarter of 2026, compared to Adjusted EBITDA loss of $3.6 million for the second quarter of 2025, an increase in adjusted EBITDA loss of $30.7 million.

Non-GAAP operating loss was $41.1 million for the second quarter of 2026, compared to non-GAAP operating loss of $10.0 million for the second quarter of 2025, an increase in non-GAAP operating loss of $31.1 million.

Six Months ended June 30,2026 Financial Results:

Net product revenue for the six months ended June 30, 2026 was $79.1 million, compared to $187.5 million for the six months ended June 30, 2025, a decrease of $108.4 million, or 58%. The decrease in net product revenue was driven by a decrease of $107.0 million, or 62%, in net product revenue for Advanced Wound Care products.

Gross profit for the six months ended June 30, 2026 was $29.6 million, or 37% of net product revenue, compared to $136.1 million, or 73% of net product revenue for the six months ended June 30, 2025, a decrease of $106.5 million, or 78%.

Operating expenses for the six months ended June 30, 2026 were $200.9 million compared to $227.0 million for the six months ended June 30, 2025, a decrease of $26.2 million, or 12%. Cost of goods sold was $49.4 million for the six months ended June 30, 2026, compared to $51.4 million for the six months ended June 30, 2025, a decrease of $1.9 million, or 4%.... (truncated)7.2 million, or 19%. R&D expense was $33.5 million for the six months ended June 30, 2026, compared to $21.0 million for the six months ended June 30, 2025, an increase of $12.4 million, or 59%.

Operating loss for the six months ended June 30, 2026 was $119.9 million, compared to an operating loss of $39.3 million for the six months ended June 30, 2025, an increase in operating loss of $80.6 million.

Total other income, net, for the six months ended June 30, 2026 was $0.5 million, compared to $1.7 million for the six months ended June 30, 2025, a decrease of $1.2 million.

Net loss for the six months ended June 30,2026 was $149.4 million, or $(1.21) per share, compared to net loss of $28.2 million, or $(0.27) per share, for the six months ended June 30, 2025, an increase in net loss of $121.2 million, or $(0.94) per share.

Adjusted net loss was $132.8 million for the six months ended June 30, 2026, compared to adjusted net loss of $20.9 million for the six months ended June 30, 2025, an increase in adjusted net loss of $111.8 million.

Adjusted EBITDA loss was $82.5 million for the six months ended June 30, 2026, compared to Adjusted EBITDA loss of $16.2 million for the six months ended June 30, 2025, an increase in adjusted EBITDA loss of $66.4 million.

Non-GAAP operating loss was $97.1 million for the six months ended June 30, 2026, compared to non-GAAP operating loss of $29.3 million for the six months ended June 30, 2025, an increase in non-GAAP operating loss of $67.7 million.

As of June 30, 2026, the Company had $46.8 million in cash, cash equivalents and restricted cash and no outstanding debt obligations, compared to $94.3 million in cash, cash equivalents and restricted cash and no outstanding debt obligations as of December 31, 2025.

Fiscal Year 2026 Outlook:

For the year ending December 31, 2026, the Company now expects:

• Total net revenue between $179.0 million and $215.0 million, representing a decline in the range of 62% to 68%, as compared to total net revenue of $564.2 million for the year ended December 31, 2025. o

Our updated total revenue guidance continues to reflect the expectation that we see sequential improvement in our revenue trends in the in the third and fourth quarters, however, at a more measured rate versus what our prior guidance assumed, resulting in a second half revenue decline in the range of approximately 64% to 74% year over year, and compared to our prior guidance range which assumed a decline in the range of 45% to 52% year-over-year.

Second Quarter Earnings Conference Call:

Management will host a conference call at 5:00 p.m. Eastern Time on August 6th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.

ORGANOGENESIS HOLDINGS INC.

UNAUDITED CONDENSED CONSOLIDATED BA

LANCE SHEETS

(amounts in thousands, except share and per share data)

## Financial statements

### Income Statement (Three Months Ended June 30, — (amounts in thousands, except share and per share data))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Revenue: | Net product revenue | 42,805 | 100,779 | 79,055 | 187,472 |
| Revenue: | Grant income | 950 | 226 | 1,928 | 226 |
| Revenue: | Total revenue | 43,755 | 101,005 | 80,983 | 187,698 |
| Operating expenses: | Cost of goods sold | 23,673 | 27,630 | 49,445 | 51,353 |
| Operating expenses: | Selling, general and administrative | 53,965 | 73,810 | 119,151 | 146,319 |
| Operating expenses: | Research and development | 18,297 | 10,395 | 33,458 | 21,035 |
| Operating expenses: | Fair value adjustment to assets held for sale | -1,188 | 1,746 | -1,188 | 8,313 |
| Operating expenses: | Total operating expenses | 94,747 | 113,581 | 200,866 | 227,020 |
| Operating expenses: | Loss from operations | -50,992 | -12,576 | -119,883 | -39,322 |
| Other income, net: | Interest income, net | 138 | 669 | 518 | 1,630 |
| Other income, net: | Other income (expense), net | -26 | 73 | 12 | 75 |
| Other income, net: | Total other income, net | 112 | 742 | 530 | 1,705 |
| Other income, net: | Net loss before income taxes | -50,880 | -11,834 | -119,353 | -37,617 |
| Other income, net: | Income tax benefit (expense) | -45,387 | 2,442 | -30,070 | 9,382 |
| Other income, net: | Net loss and comprehensive loss | -96,267 | -9,392 | -149,423 | -28,235 |
| Other income, net: | Accretion of redeemable convertible preferred stock to redemption value | -170 | -129 | -329 | -250 |
| Other income, net: | Cumulative dividend on redeemable convertible preferred stock | -2,902 | -2,681 | -5,746 | -5,308 |
| Other income, net: | Net loss attributable to common stockholders | -99,339 | -12,202 | -155,498 | -33,793 |
| Net loss per share: | Basic and diluted | -0.77 | -0.1 | -1.21 | -0.27 |
| Weighted-average common shares outstanding: | Basic and diluted | 128,674,548 | 126,853,536 | 128,238,204 | 126,576,130 |

### Income Statement (Three Months Ended June 30, — The following table presents a reconciliation of GAAP net loss to non-GAAP EBITDA and non-GAAP Adjusted EBITDA, for the periods presented: (in thousands))

| | Three Months Ended June 30, – 2026 – (Unaudited, in thousands) | Three Months Ended June 30, – 2025 – (Unaudited, in thousands) | Six Months Ended June 30, – 2026 – (Unaudited, in thousands) | Six Months Ended June 30, – 2025 – (Unaudited, in thousands) |
|---|---:|---:|---:|---:|
| Net loss | -96,267 | -9,392 | -149,423 | -28,235 |
| Interest income, net | -138 | -669 | -518 | -1,630 |
| Income tax (benefit) expense | 45,387 | -2,442 | 30,070 | -9,382 |
| Depreciation and amortization | 3,668 | 3,734 | 7,842 | 7,178 |
| Amortization of intangible assets (1) | 433 | 841 | 6,141 | 1,683 |
| EBITDA | -46,917 | -7,928 | -105,888 | -30,386 |
| Stock-based compensation expense | 3,052 | 2,542 | 6,688 | 5,909 |
| Inventory write-downs (2) |  |  | 3,327 |  |
| Restructuring charge (3) | 5,099 |  | 8,957 |  |
| Fair value adjustment to assets held for sale (4) | -1,188 | 1,746 | -1,188 | 8,313 |
| R&D program termination costs (5) | 5,588 |  | 5,588 |  |
| Adjusted EBITDA | -34,366 | -3,640 | -82,516 | -16,164 |

### Income Statement (Three Months Ended June 30, — The following table presents a reconciliation of GAAP net loss from operations to non-GAAP operating loss, for the periods presented: (in thousands))

| | Three Months Ended June 30, – 2026 – (Unaudited, in thousands) | Three Months Ended June 30, – 2025 – (Unaudited, in thousands) | Six Months Ended June 30, – 2026 – (Unaudited, in thousands) | Six Months Ended June 30, – 2025 – (Unaudited, in thousands) |
|---|---:|---:|---:|---:|
| Loss from operations | -50,992 | -12,576 | -119,883 | -39,322 |
| Amortization of intangible assets (1) | 433 | 841 | 6,141 | 1,683 |
| Inventory write-downs (2) |  |  | 3,327 |  |
| Restructuring charge (3) | 5,099 |  | 8,957 |  |
| Fair value adjustment to assets held for sale (4) | -1,188 | 1,746 | -1,188 | 8,313 |
| R&D program termination costs (5) | 5,588 |  | 5,588 |  |
| Non-GAAP operating loss | -41,060 | -9,989 | -97,058 | -29,326 |

### Balance Sheet (December 31, — (amounts in thousands, except share and per share data))

| | June 30, – 2026 | December 31, – 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 46,097 | 93,679 |
| Current assets: | Restricted cash | 747 | 652 |
| Current assets: | Accounts receivable, net | 100,937 | 217,451 |
| Current assets: | Inventories, net | 29,280 | 29,627 |
| Current assets: | Asset held for sale | 3,613 | 2,425 |
| Current assets: | Prepaid expenses and other current assets | 19,628 | 18,354 |
| Current assets: | Total current assets | 200,302 | 362,188 |
| Current assets: | Property and equipment, net | 101,531 | 103,711 |
| Current assets: | Intangible assets, net | 3,004 | 9,145 |
| Current assets: | Goodwill | 28,772 | 28,772 |
| Current assets: | Operating lease right-of-use assets, net | 49,912 | 55,749 |
| Current assets: | Deferred tax asset, net |  | 29,962 |
| Current assets: | Other assets | 22,925 | 9,203 |
| Current assets: | Total assets | 406,446 | 598,730 |
| Current liabilities: | Current portion of finance lease obligations | 859 | 9,435 |
| Current liabilities: | Current portion of operating lease obligations - related party | 4,647 | 4,258 |
| Current liabilities: | Current portion of operating lease obligations | 3,807 | 4,949 |
| Current liabilities: | Accounts payable | 29,291 | 31,949 |
| Current liabilities: | Accrued expenses and other current liabilities | 18,359 | 49,533 |
| Current liabilities: | Total current liabilities | 56,963 | 100,124 |
| Current liabilities: | Finance lease obligations, net of current portion | 10,820 | 12,788 |
| Current liabilities: | Operating lease obligations, net of current portion - related party | 25,738 | 28,237 |
| Current liabilities: | Operating lease obligations, net of current portion | 21,079 | 22,470 |
| Current liabilities: | Other liabilities | 3,714 | 1,193 |
| Current liabilities: | Total liabilities | 118,314 | 164,812 |

### Cash Flow (Six Months Ended June 30, — (amounts in thousands, except share and per share data))

| | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|
| Cash flows from operating activities: | Net loss | -149,423 | -28,235 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Depreciation and amortization | 7,842 | 7,178 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Amortization of intangible assets | 6,141 | 1,683 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Reduction in the carrying value of right-of-use assets | 4,974 | 4,077 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Non-cash interest expense | 181 | 139 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Deferred tax expense (benefit) | 29,962 | -2,292 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Provision recorded for credit losses | -2,975 | 3,116 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Loss on disposal of property and equipment | 395 | 44 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Adjustment for excess and obsolete inventories | 8,259 | 6,093 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Stock-based compensation | 6,688 | 5,909 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Fair value adjustment to assets held for sale | -1,188 | 8,313 |
| Changes in operating assets and liabilities: | Accounts receivable | 119,489 | -13,637 |
| Changes in operating assets and liabilities: | Inventories | -11,812 | -15,892 |
| Changes in operating assets and liabilities: | Prepaid expenses and other current assets and other assets | 4,810 | -12,942 |
| Changes in operating assets and liabilities: | Operating leases | -3,780 | -4,147 |
| Changes in operating assets and liabilities: | Accounts payable | -1,398 | 1,637 |
| Changes in operating assets and liabilities: | Accrued expenses and other current liabilities | -29,281 | -13,886 |
| Changes in operating assets and liabilities: | Other liabilities | 590 | 34 |
| Changes in operating assets and liabilities: | Net cash used in operating activities | -10,526 | -52,808 |
| Cash flows from investing activities: | Purchases of property and equipment | -4,246 | -7,264 |
| Cash flows from investing activities: | Net cash used in investing activities | -4,246 | -7,264 |
| Cash flows from financing activities: | Payments of withholding taxes in connection with RSUs vesting | -3,051 | -1,796 |
| Cash flows from financing activities: | Proceeds from the exercise of stock options |  | 25 |
| Cash flows from financing activities: | Principal repayments of finance lease obligations | -10,188 | -573 |
| Cash flows from financing activities: | Construction of landlord assets, net of tenant allowance | -19,476 |  |
| Cash flows from financing activities: | Net cash used in financing activities | -32,715 | -2,344 |
| Cash flows from financing activities: | Change in cash, cash equivalents and restricted cash | -47,487 | -62,416 |
| Cash flows from financing activities: | Cash, cash equivalents, and restricted cash, beginning of period | 94,331 | 136,151 |
| Cash flows from financing activities: | Cash, cash equivalents, and restricted cash, end of period | 46,844 | 73,735 |
| Supplemental disclosure of non-cash investing and financing activities: | Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock | 6,075 | 5,558 |
| Supplemental disclosure of non-cash investing and financing activities: | Change in purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities | -379 | -38 |
| Supplemental disclosure of non-cash investing and financing activities: | Landlord asset additions included in accounts payable and accrued expenses and other current liabilities, net of tenant allowances | 3,704 | $— |
| Supplemental disclosure of non-cash investing and financing activities: | Right-of-use assets obtained through finance lease obligations | -357 | $— |
| Supplemental disclosure of non-cash investing and financing activities: | Right-of-use assets obtained through operating lease obligations | $— | 1,815 |
